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Has Diagnostic and Prognostic Value as a Biomarker for
Acute Graft-versus-Host-Disease
John M. Magenau,1,2 Xuemei Qin,1,3 Isao Tawara,1 Clare E. Rogers,1 Carrie Kitko,1
Matthew Schlough,1 Daniel Bickley,1 Thomas M. Braun,4 Pil-Sang Jang,1,5
Kathleen P. Lowler,1 Dawn M. Jones,1 Sung W. Choi,1 Pavan Reddy,2 Shin Mineishi,2
John E. Levine,1,2 James L. M. Ferrara,1,2 Sophie Paczesny1The relationship between regulatory T cells (Tregs) and acute graft-versus-host disease (aGVHD) in clinical
allogeneic bone marrow transplantation (BMT) recipients is not well established. We conducted a prospec-
tive analysis of peripheral blood Tregs as determined by the frequency of CD41CD25hiFOXP31 lymphocytes
in 215 BMT patients. Autologous BMT patients (N5 90) and allogeneic BMT patients without GVHD (N5
65) had similar Treg frequencies, whereas allogeneic patients with GVHD (N5 60) had Treg frequencies that
were 40% less than those without GVHD. Treg frequencies decreased linearly with increasing grades of
GVHD at onset, and correlated with eventual maximum grade of GVHD (P\.001). In addition, frequency
of Tregs at onset of GVHD predicted the response to GVHD treatment (P 5 .003). Patients with Treg
frequencies less than the median had higher nonrelapse mortality (NRM) than patients with Tregs greater
than the median, but experienced equivalent relapse mortality, resulting in an inferior survival at 2 years
(38% versus 63%, P 5 .03). Treg frequency may therefore have important prognostic value as a biomarker
of aGVHD.
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Allogeneic bone marrow transplantation (BMT) is
a curative modality for many hematologic diseases,
but its use is limited by mortality because of acute
graft-versus-host-disease (aGVHD). Naturally occur-
ring regulatory T cells (Tregs) are mediators of
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6/j.bbmt.2010.02.026imental models [1,2]. Tregs were first defined by
a CD41CD251 phenotype [3,4], but subsequent
studies identified forkhead box protein 3 (FOXP3) as
a highly specific marker in both mouse and human T
cells with regulatory function [5-7]. High absolute
numbers of CD41FOXP31 Tregs in the donor graft
inversely correlated with aGVHD incidence and
overall survival (OS) of BMT recipients following
myeloablative conditioning in one study [8], but not
in a second [9]. Higher numbers of CD41FOXP31
lymphocytes in stem cell products depleted of T cells
have also been associatedwith a lower risk of developing
GVHD [10,11]. Experimental models suggest that
immunosuppressive therapies may adversely affect
Treg reconstitution after BMT [12-14], and studies
measuring Tregs following BMT have not consistently
correlated with either GVHD occurrence or severity
[10,11,15,16]; such discrepancies may be because of
the sample size analyzed, timing of samples, and to
various methodologies to quantify Tregs.
We prospectively analyzed Tregs using the
CD41CD25hiFOXP31 phenotype within total lym-
phocytes in 215 recipients of autologous and alloge-
neic BMT to determine the utility of this907
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FOXP3 is now accepted as a distinctive molecule for
natural and peripherally derived Tregs, and is consti-
tutively expressed at high levels in humans [17].
Although FOXP3 is expressed in CD41 cells with
low and intermediate levels of CD25, these popula-
tions contain effector cells capable of transient
FOXP3 expression, which may lack equivalent sup-
pressive function compared to CD25hi [17-19]. No
stem cell sources in this study were manipulated ex
vivo. The frequency of Tregs was analyzed at the
onset of GVHD for its correlation to disease
severity, nonrelapse mortality (NRM), response to
GVHD treatment, and OS.DESIGN AND METHODS
Study Population
Between July 2007 and July 2009, 215 BMT
patients (125 allogeneic, 90 autologous) had peripheral
blood samples collected under protocols approved by
the University of Michigan institutional review board.
After providing informed consent, samples were col-
lected within 24 hours of clinical signs of aGVHD
onset and prior to initiation of corticosteroid therapy.
In addition, samples were collected on days120,130,
160, and 1100. Approximately 70% of all possible
samples were collected. Reasons for missing samples
include patient ineligibility (second BMT/donor lym-
phocyte infusion [DLI], untreated infections, or inter-
current illness requiring intensive care), relapsed
leukemia, death, and failure to collect/technical prob-
lems. GVHD was histologically confirmed in 88% of
patients, and was staged per modified Glucksberg cri-
teria [20]. All allogeneic BMT patients received calci-
neurin inhibitors (.95% received tacrolimus) as part
of their GVHD prophylactic regimen. Patients
received unmanipulated grafts, and no patients ana-
lyzed received T cell-depleting antibodies or sera for
conditioning.Flow Cytometry of Regulatory T Cells
Fresh whole blood sample phenotyping of cell sur-
face markers was performed using CD4-PerCP-Cy5.5
(clone SK3, BD Biosciences, San Jose, CA), CD25-PE
(clone M-A251, BD Biosciences), and CD127-FITC
(clone eBioRDR5, eBioscience, San Diego, CA) anti-
bodies. Intracellular staining of FOXP3-APC (clone
PCH101, eBioscience) was performed after fixation
and permeabilization according to the manufacturer’s
recommendation. We measured Treg frequency by 3
colors (CD4, CD25, and FOXP3) or 4 colors
(CD127,CD4,CD25, and FOXP3) in 25%of samples.
FACS analysis was performed using a Canto II flow cy-
tometer (BD Biosciences) with FacsDiva software (BDBiosciences) to determine CD41CD25hiFOXP31
or CD127dimCD41CD25hiFOXP31 staining within
total lymphocytes. Absolute Treg numbers were calcu-
lated by multiplying Treg frequency by the absolute
lymphocyte count (ALC) obtained by automated dif-
ferential. Values are expressed as mean 6 SEM.
Statistical Analysis
Differences in characteristics between patient
groups were assessed with a Kruskal-Wallis test for
continuous values and Fisher’s Exact Test for cate-
goric values. Median frequencies of Tregs were com-
pared using a Kruskal-Wallis test. Survival was
modeled using Cox regression methods. Relapse mor-
tality and NRM were modeled using cumulative inci-
dence regression methods as described in Fine and
Gray [21]. The association between Treg frequency
and response to therapy was calculated using chi-
squared analysis. Wilcoxon signed rank tests were
used to compare the Treg frequency at the onset of
GVHD and 4 weeks after treatment for 25 responders
and 15 nonresponders.RESULTS
Phenotypic Characterization of Tregs
The population of CD4 lymphocytes expressing
very high levels of CD25 has been shown to express
high levels of FOXP3 and exert dose-dependent inhi-
bition on CD41CD252 T cells [22]. As expected, we
observed the highest FOXP3 expression among the
CD25111 (CD25hi) lymphocyte subset, compared to
CD2511 and CD251 lymphocyte subsets in autolo-
gous and allogeneic patient samples (Figure 1). The
mean FOXP3 expression in CD41CD25hi cells was
similar among recipients of autologous BMT (71.0%
6 2.1%), allogeneic BMT with no GVHD (68.9% 6
2.5%), and allogeneic BMT with GVHD (64.1% 6
3.2%) (Figure S1). The CD41CD25hiFOXP31
phenotype had dim CD127 expression in .95% of
cells, consistent with prior reports [23,24]. But
CD41CD251CD127dim T cells include cells that
lack suppressive function and produce interleukin
(IL)-17, IL-2, and interferon (IFN)-g [18,25]. We
therefore used the CD41CD25hiFOXP31 phenotype
to define the Treg population.
Treg Frequencies following Autologous and
allogeneic BMTwithout GVHDAre Similar
We first compared Tregs by measuring
CD41CD25hiFOXP31 cells from freshly acquired pe-
ripheral blood samples in autologous BMTpatients (N
5 90) and allogeneic BMT recipients without GVHD
(N5 65). Characteristics of autologous and allogeneic
populations are shown in Table 1A. High-risk
Figure 1. Phenotypic characterization of Tregs. Representative flow data from a patient following allogeneic transplantation. Fresh whole blood was
stained with CD4-PerCP-Cy5.5 and CD25-PE antibodies followed by intracellular staining for FOXP3-APC. Treg frequency was determined using
a Canto II flow cytometer (BD Biosciences) to identify CD41CD25hiFOXP31 triple-positive cells within the total lymphocyte population. Treg fre-
quency was performed in triplicate for each sample. (A) The total lymphocyte population (R1) was identified by light scatter after backgating on the
CD41 population. On the right are histograms of FOXP31 expression (filled) gated on CD41CD251, CD41CD2511, and CD41CD25111
(CD41CD25hi) lymphocyte subsets. Analysis was restricted to the CD41CD25hi lymphocyte subset (R2), which was identified in R1. The frequency
of CD41CD25hiFOXP31 lymphocytes was calculated by multiplying the percentage of CD41CD25hi cells by the percentage of FOXP31 cells within
CD41CD25hi.
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between groups, but days to sample were similar. Fre-
quencies of Tregs were similar in patients who did not
develop GVHD after either autologous (1.09 6 0.10)
or allogeneic BMT (1.06 6 0.10) (P 5 .84)
(Figure 2A). These frequencies were also similar to
those obtained from 6 healthy donors (1.17 6 0.16).
However, absolute Treg numbers were reduced in
allogeneic BMT patients with no GVHD compared
to autologous BMT patients (P 5 0.04) (Figure 2B),
as a result of lower ALCs in allogeneic BMT patients
(Figure S2).Decreased Treg Frequencies at Time of GVHD
Onset and 3-14 Days Prior to GVHD
We compared samples at GVHD onset to samples
from patients without GVHD, such that both groups
were balanced for time of acquisition. Characteristics
of allogeneic patients according to GVHD status are
shown in Table 1B. Patients were not significantly dif-
ferent for age, nonmalignant disease, conditioning
intensity, and median day of sample acquisition. As ex-
pected, recipients of grafts from donors who were not
family members or who were not HLA-matched wereoverrepresented in the GVHD group. Patients with all
grades of GVHD had a 40% lower Treg frequency
than patients without GVHD (P\ .001) (Figure 2A).
We calculated the absolute numbers of Tregs by mul-
tiplying the frequency of CD41CD25hiFOXP31 cells
by the ALC, which was slightly higher in GVHD pa-
tients (1.13 6 1.15) compared to patients without
GVHD (Figure S2). The absolute Treg numbers re-
mained lower in patients withGVHD compared to pa-
tients without GVHD (P 5 .01) (Figure 2B). We also
analyzed the ratio of Tregs to conventional T cells
(Tconv) by dividing the CD41CD25hiFOXP31 fre-
quency by the CD41CD252FOXP32 frequency.
Tconv frequencies were similar in the 2 groups (11.8
6 0.97 versus 10.56 0.91). The mean Treg/Tconv ra-
tio was significantly lower in patients with GVHD (P
\ .001) (Figure 2C).
Fourteen patients had paired samples available
3-14 days prior to GVHD onset, and these were com-
pared to 15 paired samples in patients without GVHD.
Treg frequencies prior to aGVHD significantly
decreased in the majority of patients (P 5 .003)
(Figure 3A), whereas no decrease occurred over a sim-
ilar time interval in allogeneic patients without
GVHD (P 5 0.7) (Figure 3B).
Table 1B. Characteristics of GVHD Positive and GVHD
Negative Patients
Characteristic No GVHD GVHD P-value
Patients 65 60
Age, years
Median 50 52 .24
Range 1-67 1-66
Related donor, % (no.) 60% (39) 33% (20) .004
Matched donor, % (no.) 86% (56) 67% (40) .01
Stem cell source, % (no.)
Peripheral blood, % (no.) 86% (56) 78% (47) .12
Bone marrow, % (no.) 11% (7) 8% (5)
Cord blood, % (no.) 3% (2) 13% (8)
Full intensity conditioning, % (no.) 74% (48) 70% (42) .69
Malignant disease, % (no.) 92% (60) 98% (59) .21
High risk malignancy, % (no.) 32% (21) 47% (28) .12
GVHD prophylaxis, % (no.)
TAC/MMF 37% (24) 42% (25) .41
TAC/MTX 38% (25) 25% (15)
TAC/MMF or MTX/Etanercept 11% (7) 17% (10)
Other‡ 14% (9) 17% (10)
Days to sample
Median 29 29 .29
Range 16-106 14-111
Days to GVHD onset
Median 29
Range 14-111
Onset GVHD grade, % (no.)
Grade I 46% (28)
Grade II 44% (26)
Grade III-IV 10% (6)
Maximum GVHD grade, % (no.)
Grade I 28% (17)
Grade II 50% (30)
Grade III-IV 22% (13)
Organ target at GVHD onset, % (no.)
Skin only 68% (41)
Gut only 21% (13)
Liver only 2% (1)
Skin + gut/liver 9% (5)
TAC indicates tacrolimus; MTX, methotrexate; SIRO, sirolimus; MMF,
mycophenolate mofetil; GVHD, graft-versus-host disease.
*Malignant diseases include Hodgkin disease (HD), chronic lymphocytic
leukemia (CLL), acute myelogeneous leukemia (AML), myelodysplastic
syndrome (MDS), non-Hodgkin lymphoma (NHL), acute lymphoblastic
leukemia (ALL), multiple myeloma (MM), and myeloproliferative disease
(MPD).
†AML and ALL >CR2, induction failure or refractory, AML arising from
antecedent MDS, CML in blast or accelerated phases, HD and NHL
>CR2 or refractory, progressive MM.
‡Other GVHD prophylaxis include: TAC/SIRO (n5 3), TAC/MTX/SIRO
(n5 1), TAC/MMF/MTX (n5 11), MMF/Cyclosporine (n5 3), MTX/cy-
closporine (n 5 1).
Table 1A. Characteristics of Autologous and Allogeneic
Patients with no GVHD
Characteristic Auto Allo P-value
Patients 90 125
Age, years
Median 55 50 .004
Range 6-70 1-67
Days to sample
Median 32 29 .14
Range 14-119 14-111
Malignant disease, % (no.)* 98% (88) 95% (119) .47
High risk malignancy, % (no.)† 14% (13) 39% (49) <.001
Figure 2. Regulatory T cells (Tregs) at GVHD onset. Fresh blood sam-
ples from autologous and allogeneic transplant patients (N5 215) were
acquired within 24 hours of acute GVHD onset or at equivalent time
points following transplantation. Mean (A) Treg frequencies, (B) absolute
Treg numbers, and (C) Treg/Tconv frequencies for autologous BMT pa-
tients, allogeneic BMT patients with no GVHD, and allogeneic BMT pa-
tients with GVHD. Error bars represent the SEM.
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Severity at Onset and Eventual Maximum
GVHD Grade
We next hypothesized that Treg frequency would
correlate with GVHD severity at onset. Frequencies of
Tregs decreased in an almost linear fashion with each
increasing grade of GVHD, and were significantly
reduced in patients with equal to or greater than grade
Figure 3. Treg frequencies prior to GVHD onset. (A) Paired analysis in GVHD patients (N5 14) comparing Treg frequencies at GVHD onset to prior
timepoints (3-14 days). (B) Treg frequencies from matched controls with no GVHD (N5 15) over an equivalent 3 to 14-day interval. Bars denote mean
values.
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.001) (Figure 4A). A similar pattern was observed with
absolute Treg numbers, but the variability within
groups was greater, reducing the statistically signifi-
cant differences between groups (Figure 4B). We
also assessed whether Treg frequency at onset corre-
lated with eventual maximum overall GVHD. The
median interval between GVHD onset and eventual
maximum overall GVHD grade was 14 days, with 11
of 28 (39%) patients progressing from grade I to
higher GVHD grades. Treg frequency at GVHD on-
set was significantly reduced in patients who eventually
developed maximum grade II-IV GVHD compared to
patients without GVHD or who remained at grade I
GVHD (P\ .001) (Figure 4C).Treg Frequency Has Prognostic Value at GVHD
Onset
Given these correlations, we next evaluated
whether Treg frequency at onset would predict out-
comes in the 60 patients with GVHD by dividing pa-
tients according to their median Treg frequency
(0.5%). As shown in Figure 5A, patients with GVHD
whose Treg frequency was less than the median had
a significantly greater NRM at 1 year (41% [95% con-
fidence interval, (CI), 23%-61%]) than patients with
Treg frequencies equal to or greater than the median
(7% [95% CI, 2%-24%], P 5 .01). aGVHD was the
major cause of death in patients with low Treg fre-
quencies (27% versus 3%, P 5 .03) (Table S1).
Relapsemortality was similar: 21% (95%CI, 9-40)
in patients with low Treg frequencies compared to
30% (95% CI, 12-57) in patients with high Treg fre-
quencies (P 5 .86) (Figure 5B). The OS at 2 years
was significantly less in patients with low Treg fre-
quencies (38% [95% CI, 23%-63%]) than in patients
with high Treg frequencies (63% [95% CI, 43%-
91%]) (P 5 .03) (Figure 5C).
The difference in OS according to Treg frequency
at GVHD onset remained significant after adjustingfor ALC at time of sample collection and other impor-
tant prognostic factors such as, age, donor type, degree
of HLA-match, and conditioning intensity (hazard ra-
tio [HR] of 2.43 [95% CI: 1.01-5.87], P5 .05). When
both Treg frequency ($0.5% versus\0.5%) and max-
imum GVHD grade (Grades I-II versus III-IV) were
analyzed in a simultaneous Cox regression analysis
the Treg frequency remained significant (HR of 2.33
[95% CI: 0.96-5.66], P 5 .05).
Treg Frequency and Response to Treatment
Because Treg frequency had prognostic value in
GVHD, we analyzed if Treg frequency at GVHD
onset predicted response to treatment. Four weeks
following GVHD onset, patients with no GVHD
(N 5 29) or stage I GVHD of the skin (N 5 8)
were classified as complete responders (N 5 37),
whereas patients with more advanced GVHD were
classified as nonresponders (N 5 20). Three patients
were not evaluable because of death or progressive
disease. In patients with high Tregs (N 5 28) at
GVHD onset, 24 (86%) had complete responses,
whereas in patients with low Tregs (N 5 29) only
13 (45%) had complete responses (P 5 .003). How-
ever, responders had more GVHD grade I at diagno-
sis (54% versus 25%, P 5 .05). When patients
achieving a complete resolution of GVHD (N 5
29) were evaluated, Treg frequency remained associ-
ated with treatment response (P 5 .005). Paired sam-
ples at onset of GVHD and 4 weeks following
treatment were available for 25 of 37 responding pa-
tients and 15 of 20 nonresponding patients. As shown
in Figure 6, responding patients showed a significant
increase of their Treg frequency 4 weeks after treat-
ment (P 5 .02).DISCUSSION
In this study, we evaluated Treg asmeasured by the
CD41CD25hiFOXP31 phenotype for its value as
Figure 4. Treg frequencies and GVHD severity. Fresh blood samples
from allogeneic transplant patients with GVHD (N5 60) were acquired
within 24 hours of aGVHD onset and analyzed according to GVHD se-
verity. (A) Mean Treg frequencies, (B) absolute Treg numbers by grade of
GVHD at onset, and (C) mean Treg frequencies by eventual maximum
overall GVHD grade. The median interval between GVHD onset and
eventual maximum overall GVHD grade was 14 days. Error bars repre-
sent the SEM.
Figure 5. Treg frequencies are correlated with clinical outcomes. The
median T reg frequency was 0.5% in allogeneic BMT patients at time of
GVHD onset (N 5 60). (A) NRM, (B) relapse mortality, and (C) OS in
patients with GVHD divided according to the median Treg frequency:
high Treg $0.5% (N 5 30) or low Treg\0.5 (N 5 30).
912 Biol Blood Marrow Transplant 16:907-914, 2010J. M. Magenau et al.a cellular biomarker at GVHD onset. Because Tregs
rely on exogenous IL-2 to function [17], situations
characterized by impaired IL-2 production might alter
Treg frequency. Calcineurin inhibitors, are frequently
administered to allogeneic BMT patients as in this
study, and have been shown to impair the expansion
Figure 6. Treg frequencies at 4 weeks according to treatment re-
sponse. Mean (6SEM) Treg frequencies were measured on paired sam-
ples at onset and 4 weeks after treatment in 25 patients with complete
response or near complete response (CR) and 15 nonresponders (NR).
Biol Blood Marrow Transplant 16:907-914, 2010 913Treg Frequency as a Biomarker for GVHDand suppressive function of Tregs in experimental
models [12-14]. Treg frequency at day 130 after
autologous and after allogeneic BMT in patients
without GVHD were similar, suggesting that
allogeneic transplant recipients receiving tacrolimus
have similar Treg recovery to autologous transplant
recipients without tacrolimus. However, absolute
Tregs were less in allogeneic BMT patients with no
GVHD compared to autologous BMT patients, an
effect attributed to lower absolute lymphocyte
counts. This supports a study in which low-dose cyclo-
sporine, which has similarmechanistic properties to ta-
crolimus, had no effect on CD41FOXP31 cell
frequencies at day 130 following T cell-depleted
BMT [10].
Previous studies measuring Tregs following BMT
have not analyzed their frequency at time of GVHD
onset. We observed that Treg frequencies measured
within 24 hours of GVHD diagnosis were significantly
less than allogeneic patients without GVHD, and
correlated inversely with GVHD severity. This
association supports an earlier report from Johns
Hopkins University that demonstrated a correlation
of FOXP3 mRNA with GVHD severity when using
samples at GVHD onset [26]. This finding has not
been consistently confirmed in other studies [10,11].
As a single biomarker, Treg frequency at GVHD
onset had only modest diagnostic value (areas under
the curve 5 0.69), but the inverse relationship
between Treg frequency and GVHD severity
demonstrates its utility. It should also be noted that
we measured Tregs in the peripheral blood, not in
the target tissue, where they presumably exert their
greatest effect. Interestingly, in a small cohort of
patients, we observed an overall decrease in Tregs
prior to clinical onset of GVHD, suggesting that
a decline in Treg frequency may herald onset of thedisease. Although these analyses are correlative in
nature, this observation indicates that systematic
measurements of Treg frequencies may be able to
predict the occurrence of GVHD, and extends the
findings of a previous study in which the frequency
of CD41CD251 T cells decreased during the initial
phases of GVHD [27].
Importantly, Treg frequency measured at GVHD
onset may have prognostic value, which is a major fea-
ture of clinically relevant biomarkers [28]. In our study,
Treg frequency of\0.5% correlated with poor out-
comes (maximum overall GVHD grade, NRM, OS).
This finding suggests that prospective measurement
of Treg frequency at GVHD onset may improve stan-
dard clinical GVHD grading and further risk stratified
groups of patients. Identification of patients at high risk
for severe GVHD early in their transplant course may
impact clinical decisions to include more stringent
monitoring and/or intense treatment.
Consistent with its prognostic value, Treg fre-
quency at GVHD onset correlated with eventual treat-
ment response at 4 weeks. It is not known whether
altering immunosupression in patients with low Treg
frequencies might subsequently improve outcomes
through the in vivo expansion of Tregs. Recently,
treatments such as rapamycin and extracorporeal pho-
tophoresis have been shown to increase Tregs and pro-
tect from experimental GVHD [29-31]. Prospective
studies of Treg expansion for the treatment and
prevention of GVHD in high risk patients are
therefore warranted.ACKNOWLEDGMENTS
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